Summary

Eligibility
for females ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Edwin Alvarez

Description

Summary

This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product. Backfill cohorts will enroll additional subjects at doses deemed to be safe for a total enrollment of up to 12 subjects per each backfill cohort on the protocol.

Official Title

An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients with Resistant/Refractory Epithelial Ovarian Cancer

Details

Keywords

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Genital Neoplasm, Female, Abdominal Neoplasm, Recurrence, ovarian cancer, fallopian tube cancer, primary peritoneal cancer, platinum resistant, Neoplasms, Ovarian Epithelial Carcinoma, Glandular and Epithelial Neoplasms, Female Genital Neoplasms, Abdominal Neoplasms

Eligibility

Locations

  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco California 94158 United States
  • U of Washington - Fred Hutchinson Cancer Center
    Seattle Washington 98195 United States

Lead Scientist at UCSF

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Arsenal Biosciences, Inc.
ID
NCT05617755
Phase
Phase 1 research study
Study Type
Interventional
Participants
About 19 people participating
Last Updated